Caelyx 20 mg Injection 10 ml is an anti-cancer medicine used in the treatment of cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. Caelyx 20 mg Injection 10 ml is primarily used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer (abnormal growth in the cells of the breast). It is also used to treat neuroblastoma (cancer that starts in nerve cells and primarily affects children) and Wilms' tumor (a form of kidney cancer that affects children).

Caelyx 20 mg Injection 10 ml contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, destroying DNA and RNA synthesis.

Caelyx 20 mg Injection 10 ml may cause certain side effects such as nausea, headache, abdominal pain, loss of appetite, vomiting, dizziness, mouth sores, tiredness, back pain, red discoloration of urine, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Caelyx 20 mg Injection 10 ml. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Caelyx 20 mg Injection 10 ml should be avoided if you are allergic to it or any other components of this medicine. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression, and severe liver disease. Hence, if you have any such conditions, inform your doctor. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause adverse effects. Caelyx 20 mg Injection 10 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.

Caelyx 20 mg Injection 10 ml contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis. Caelyx 20 mg Injection 10 ml is also used in the treatment of acute lymphoblastic leukaemia, acute myeloblastic leukaemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumour, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma

Caelyx 20 mg Injection 10 ml should be avoided if you are allergic to it. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression and severe liver disease. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause serious adverse effects. Caelyx 20 mg Injection 10 ml is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Do not stop receiving Caelyx 20 mg Injection 10 ml without a doctor’s advice, as it can cause serious health conditions. Caelyx 20 mg Injection 10 ml is known to cause secondary malignancies, tissue necrosis, cardiomyopathy and septic shock in some patients. Hence careful monitoring of the patient is needed while receiving the medicine.

• Avoid intercourse while on treatment with Caelyx 20 mg Injection 10 ml.
• Regular complete blood count monitoring is advised.  Also, monitoring of liver function is important while receiving Caelyx 20 mg Injection 10 ml.

• According to postmarketing reports, juvenile children receiving doxorubicin hydrochloride are at risk of developing late cardiovascular dysfunction. Risk factors include early age during treatment (particularly five years), large cumulative dosages, and receipt of multimodal modality therapy. All pediatric patients who have received doxorubicin hydrochloride should undergo long-term cardiovascular monitoring.